![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Thursday, March 06, 2014 3:33:48 PM
Larry Smith reprinted Doc Logic's statement on January 28, 2014. It's so enlightening, I thought I would also reprint it.
Doc logic said that investors must understand the need for a more complete antigen presentation (as is the case with DCVax-L) to the dendritic cells is only one part of what DCVax-L does. Another important aspect of the product is that it takes signaling compounds to the proper sites so that helper T-cells and killer T-cells can be properly informed and activated and T-regulator cells can be inactivated so that the proper immune response can occur.
DCVax-Direct has more than 10x the amount of signaling compounds on each dendritic cell than those of DCVax-L. These compounds in the tumor microenvironment are immediately put to work and because the tumor has been damaged already, as per trial protocol, the ability of the dendritic cell to identify antigens is improved and mobility is not more fully impaired as would be the case with a healthy tumor environment.
An article from Neuro Oncol magazine dated April12, 2010 titled “Intratumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment” which essentially states that intradermal (i.e. DCVax-L) vaccination is improved by intratumoral (ie. DCVax-Direct) vaccination because the microenvironment of the tumor is changed by doing so. This evidence is only a small part of the evidence that I have found that supports a long term investment in NWBO.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • Jul 30, 2024 8:00 AM
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM